Study of the CD40 Agonistic Monoclonal Antibody APX005M

Summary

This study is a phase 1 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M in adults with solid tumors. Study is intended to establish the maximum tolerated dose and the overall safety and tolerability of APX005M in 3 different administration schedules.

Timeline

Start

2015-05

Primary completion

2018-06-13

Completion

2018-06-19

Drugs

Indications